Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial - Top-Institutions - MDSpire

Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial

  • By

  • Lin Cai

  • Xiaohua Wang

  • Litao Zhang

  • Guoqiang Zhang

  • Liming Wu

  • Baoqi Yang

  • Zudong Meng

  • Jihai Shi

  • Guangming Han

  • Aihua Wei

  • Shanshan Li

  • Yi Zhao

  • Juan Su

  • Nianjin Wei

  • Siying Liu

  • Ran Liu

  • Wei Liu

  • Min Fang

  • Xiaoqing Zhang

  • Jianzhong Zhang

  • March 22, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

  • #2

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Pharmacology

  • #3

    National Psoriasis Foundation Research Center at Northwestern University
    National Psoriasis Foundation Research Center at Northwestern University

    Chicago, IL

    Key Differentiators

    • Dermatology
    • Psoriasis Research
    • Clinical Trials

  • #4

    Peking University First Hospital
    Peking University First Hospital

    Beijing, Beijing

    Key Differentiators

    • Dermatology
    • Clinical Trials
    • Immunology

  • #5

    The University of Manchester - Salford Royal NHS Foundation Trust
    The University of Manchester - Salford Royal NHS Foundation Trust

    Manchester, England

    Key Differentiators

    • Dermatology
    • Clinical Trials
    • Immunology

Original Source(s)

Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial

  • by Lin Cai, Xiaohua Wang, Litao Zhang, Guoqiang Zhang, Liming Wu, Baoqi Yang, Zudong Meng, Jihai Shi, Guangming Han, Aihua Wei, Shanshan Li, Yi Zhao, Juan Su, Nianjin Wei, Siying Liu, Ran Liu, Wei Liu, Min Fang, Xiaoqing Zhang, Jianzhong Zhang

  • March 22, 2026

Related Content

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

Evaluation of the Safety and Efficacy of Scheduled Temporary Withdrawal Versus Ongoing Maintenance of Interleukin Inhibitors in Psoriasis Patients: A Systematic Review and Network Meta-Analysis

Assessment of Tildrakizumab's Effectiveness and Safety in Patients with Moderate-to-Severe Plaque Psoriasis and Diabetes: Combined Analysis from reSURFACE 1 and reSURFACE 2 Trials